VERASTEM ONCOLOGY
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
117 Kendrick St Ste 500, Needham, Massac...Phone Number
(781) 292-4200Website
www.verastem.comRevenue
$49.6 MillionStock Symbol
VSTMIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About VERASTEM ONCOLOGY
Verastem Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for patients with cancers driven by abnormalities in the RAS and MAPK signaling pathways. The company is dedicated to advancing targeted therapies that address significant unmet medical needs by focusing on the underlying biological mechanisms responsible for cancer development, progression, and resistance to treatment.Explore more
VERASTEM ONCOLOGY Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is VERASTEM ONCOLOGY your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if VERASTEM ONCOLOGY has recently received funding, and reach out quickly before it becomes old news!
Check out if VERASTEM ONCOLOGY is spiking on competitors!
Product Launch: Get notified when VERASTEM ONCOLOGY launches new products
VERASTEM ONCOLOGY, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at VERASTEM ONCOLOGY
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once VERASTEM ONCOLOGY has new funding data
Click to see if VERASTEM ONCOLOGY had a recent Job posting/layoffs
Earning: See what the market has to say on VERASTEM ONCOLOGY recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined VERASTEM ONCOLOGY as Masked Content
Find 3 more new buyers
Compare Similar Companies to VERASTEM ONCOLOGY
Compare insights from companies similar to VERASTEM ONCOLOGY, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
VERASTEM ONCOLOGY is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
VERASTEM ONCOLOGY is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about VERASTEM ONCOLOGY.
VERASTEM ONCOLOGY financials insights
Gather financial insights about VERASTEM ONCOLOGY, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Stock Offering
$63.3M
Unspecified
$2M
2014
Other Financing Round
$3.9M
2015
Stock Offering
$50.9M
2017
Stock Offering
$25M
2018
Multiple Rounds
$131.1M
2020
Debt
$4.8M
Share Placement
$100M
2022
Debt
$150M
VERASTEM ONCOLOGY Tech Stack
A closer look at the technologies used by VERASTEM ONCOLOGY
Most Recent Scoops
Open Position
Open Position
Project
Verastem has reported that 13 of 14 patients with elevated baseline CA19-9 levels in its 900 mg PDAC cohort achieved at least a 50% reduction in CA19-9 with several exceeding 90% reduction typically manifesting within three weeks, representing substantially higher rates than those reported for combination cytotoxic chemotherapy regimens in relapsed and frontline PDAC.
Medical Research
Project
Verastem has reported a patient case study in which a 55-year-old male with KRAS G12D-mutated metastatic pancreatic cancer achieved a confirmed partial response by RECIST a 47% reduction in the sum of longest diameters of target lesions following 12 weeks of single-agent oral VS-7375 at 900 mg once daily, with substantial pain resolution within one week and no treatment-related adverse events reported.
Medical Research
Project
Medical Research
VERASTEM ONCOLOGY News & Media
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors - Yahoo Finance
BOSTON, May 26, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of his term on May 21, 2026.Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment
Verastem, Inc. (NASDAQ:VSTM) is one of the top long-term biotechnology stocks to buy. On October 23, Verastem, Inc. (NASDAQ:VSTM) reported positive preliminary results from an ongoing phase 1/2a dose-escalation trial of vs-7375, an oral KRAS G12D (on/off) inhibitor, in patients with KRAS G12D-mutant solid tumors. The preliminary safety and tolerability data indicate that VS-7375 can […]Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects
Verastem, Inc. (NASDAQ:VSTM) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company progresses with its Phase 3 ovarian cancer trial while AVMAPKI FAKZYNJA CO-PACK generates revenue. Verastem, Inc. (NASDAQ:VSTM), operating from its headquarters in Massachusetts, is a development-stage biopharmaceutical company. Its focus is on discovering and commercializing novel cancer therapies, […]Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the primary analysis of the Phase 2 RAMP 201 clinical trial was published online in the Journal of Clinical Oncology (JCO). The data reported in the publication showed that avutometinib plus defactinib demonstrated a confirmed overall response rate (ORR) of 31% in all patients with recurrent low-grade
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding VERASTEM ONCOLOGY
Sign Up For FreeTo access detailed company insights
Verastem Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for patients with cancers driven by abnormalities in the RAS and MAPK signaling pathways. The company is dedicated to advancing targeted therapies that address significant unmet medical needs by focusi... Read More
